Clinical Trial Search

Primary: Off-medication/On-stimulation Motor Function Score of the Unified Parkinson's Disease Rating Scale (UPDRS Part III) — -8.2; -9.1 units on a scale — p=0.808

Primary: Progression-free Survival (PFS) — 53.2; 56.6; 48.6; 49.0 percentage of participants

Primary: Remission — 38.5; 31.0; 39.5 percentage of participants

Primary: Cmax of Faldaprevir (BI 201335) — 3520; NA; 8780; 9950 ng/mL — p=1.0000

Primary: Overall Asymmetry Index — 0.064; 0.352; 0.541; 1.481 unit-less index (0 = perfect symmetry)

Primary: Knowledge — 6.0; 5.7; 5.5 Units on a scale

Primary: Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB) for PF-06263276 4% Solution in Comparison to Corresponding Vehicle at Day 12 — 358.9; 353.1; 17.7…

Primary: Change From Baseline in Depression Symptom Severity at 12 Weeks — 18; 17.7 Total score on CDRS-R

Primary: Change in Physician-rated Scale of NLDO From Baseline to Follow-Up Visit at Week 8 or From Baseline to Time of Treatment Failure, if Earlier. — 7; 10; 1; 1 participants

Primary: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-infinity). — 191; 192; 179; 191 h*ng/mL

Primary: Patient-perceived Duration of Analgesia — 33; 41; 46.5 hours

Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants

Primary: Percentage of Patients With a Minimally Detected Decline (MDD) in Quality of Life (QOL) — 17; 18; 41; 19 percentage of patients

Primary: Intervention Compliance — 1 participants

Primary: Muscle Microvascular Function — 3.7; 4.0 10^3 mL*min^-1*100ml^-1*mmHg^-1